Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical trial of TR-C 19 to treat COVID-19 patients.

Trial Profile

Clinical trial of TR-C 19 to treat COVID-19 patients.

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 22 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TR-C 19 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions

Most Recent Events

  • 14 May 2020 According to a VSY Biotechnology media release, TR-C 19 is now at the authority approval stage for usage on voluntary COVID-19 patients and clinical trial.
  • 14 May 2020 According to a VSY Biotechnology media release, Clinical and voluntary trials will be organized in partnership with SBU. The initial results of voluntary patient trials will be shared publicly in the coming weeks.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top